WEBINAR – A Groundbreaking Technology for Vaccine Development: New Techniques in Viral Cytopathogenicity Assessment using Real Time Cell Analysis

Traditional measurement of viral titers during vaccine development often involve cytopathic effect (CPE) quantification by plaque assays or tissue culture infectious dose (TCID50) assays, which are based on subjective visual interpretation of cell culture deterioration. These labor-intensive endpoint assays can only provide a mere snapshot of the infection process and the overall kinetics information is inherently missing.  

The xCELLigence® Real-Time Cell Analysis technology, a unique live cell assay which allows label-free and continuous tracking of CPE progression in virus-infected cells, provides a dramatically simplified workflow for diverse virology assays, including but not limited to:

  • Virus titer determination
  • Detection and quantification of neutralizing antibodies
  • Antiviral drug discovery & development
  • Oncolytic virus characterization
  • Quantitative comparison of fitness between different virus strains

 

Webinar Details:

Thursday, November 29th, 2018

  • 07:00 – 08:10 AM PST
  • 10:00 – 11:10 AM EST
  • 04:00 – 05:10 PM CET

 

Featured Presentations:

Loic Benair
Associate Scientist
Sanofi Pasteur, France

xCELLigence: a new real-time and high-throughput tool for viral infectivity titration
The classical cell-culture methods, such as cell culture infectious dose 50% (CCID50) assays, are time-consuming, end-point assays currently used during the development of a viral vaccine production process to measure viral infectious titers. However, they are not suitable for handling the large number of tests required for high-throughput and large-scale screening analyses. Impedance-based bio-sensing techniques used in real-time cell analysis (RTCA) to assess cell layer biological status in vitro, provide real-time data. In this talk, we will show the assessment of RTCA virus-titration assay as an alternative method to the classical CCID50 assay during the development of viral vaccine production process.

 

Brandon Lamarche, Ph.D.
Senior Scientist
ACEA Biosciences

Monitoring Virus Cytopathic Effects in Real-Time: Diverse Applications Ranging from Vaccine Development and Drug Discovery to Quantification of Neutralizing Antibodies
When infected by a virus, host cells typically display phenotypic changes (such as swelling, detachment, and lysis) that are collectively referred to as a cytopathic effect (CPE).  Although CPEs can be a useful tool for monitoring viral infection, traditional methods like the plaque assay attempt to quantify CPEs manually and are therefore labor intensive, subjective, and suffer from poor reproducibility.  Each of these challenges is overcome by the xCELLigence Real-Time Cell Analyzer.  Using gold biosensors embedded within the bottom of microtiter plate wells, the xCELLigence instrument continuously monitors virus-induced changes in host cell number, cell size, cell-substrate attachment strength, and cell-cell adhesion (i.e. barrier function).  The high sensitivity and reproducibility, simple workflow, and real-time kinetics of this assay make it a powerful tool for diverse virology applications.  In this talk I will explain how the xCELLigence biosensors monitor CPEs, discuss the workflow, and will demonstrate the utility of this instrument for virus titer determination,  quantification of neutralizing antibodies, antiviral drug discovery/development, evaluating oncolytic virus efficacy and assessing virus quality/fitness.